Proteostasis Therapeutics Inc (PTI)

2.00
NASDAQ : Health Care
Prev Close 2.04
Day Low/High 1.94 / 2.10
52 Wk Low/High 1.94 / 18.99
Avg Volume 189.40K
Exchange NASDAQ
Shares Outstanding 25.10M
Market Cap 51.21M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Proteostasis Therapeutics Reports Preliminary Data From Phase 1 Study Of PTI-428 In Patients With Cystic Fibrosis

Proteostasis Therapeutics Reports Preliminary Data From Phase 1 Study Of PTI-428 In Patients With Cystic Fibrosis

Screening Initiated in Phase 2 Portion of PTI-428 Study, 28-day Dosing Cohort

Proteostasis Therapeutics Announces Clinical And Regulatory Progress Across Pipeline Programs

Updates Announced During the 40th European Cystic Fibrosis Society Conference

Oversold Conditions For Proteostasis Therapeutics (PTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DISCK, FOR, FPI, IAG, TITN Downgrades: PATI, SCKT, TCRD, TRC, UBP Initiations: PTI Read on to get TheStreet Quant Ratings' detailed report:

RSI Alert: Proteostasis Therapeutics (PTI) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies are scooping up shares of their own stock lately.

Proteostasis Therapeutics Announces Scientific Presentations On New Data At 30th Annual North American Cystic Fibrosis Conference

Proteostasis Therapeutics Announces Scientific Presentations On New Data At 30th Annual North American Cystic Fibrosis Conference

Company to Host Analyst and Investor Event Thursday, Oct. 27 at 8:00 p.m. ET

PTI Crosses Above Average Analyst Target

PTI Crosses Above Average Analyst Target

In recent trading, shares of Proteostasis Therapeutics Inc have crossed above the average analyst 12-month target price of $17.00, changing hands for $19.41/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Proteostasis Therapeutics Issues Mid-Year Corporate Update On Cystic Fibrosis Pipeline Programs

Proteostasis Therapeutics Issues Mid-Year Corporate Update On Cystic Fibrosis Pipeline Programs

Preliminary Biomarker Data Confirms PTI-428 Activity on CFTR mRNA in Human Subjects

Proteostasis Therapeutics Enters Oversold Territory (PTI)

Proteostasis Therapeutics Enters Oversold Territory (PTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

What You Need to Know About Biotech IPOs This Year

What You Need to Know About Biotech IPOs This Year

Here's the lowdown on the biotech companies that have come public this year.

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential For Genotype-Agnostic And Combination Therapies For People With Cystic Fibrosis

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential For Genotype-Agnostic And Combination Therapies For People With Cystic Fibrosis

Data Presented at 13th Annual ECFS Basic Science Conference on Novel Therapies Targeting Cystic Fibrosis

Proteostasis Therapeutics, Inc. Announces Scientific Presentations At 13th Annual European Cystic Fibrosis Society Basic Science Conference

Proteostasis Therapeutics, Inc. Announces Scientific Presentations At 13th Annual European Cystic Fibrosis Society Basic Science Conference

Company to Hold Investor Conference Call and Webcast to Outline Scientific and Corporate Updates on March 30, 2016

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

JLL Partners (“JLL”), a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company, today announced the creation of a new company, which will be a leading ...

Patni Computer Systems Ltd. Stock Upgraded (PTI)

Patni Computer Systems (NYSE:PTI) has been upgraded by TheStreet Ratings from a hold to buy.